Abstract:OBJECTIVE:(Background): Alzheimer's disease (AD), clinically characterized by the progressive neurodegenerative condition and cognitive impairment, is one of the main causes of disability in elder people worldwide. Recently, several animal studies indicated that the 'gut-brain' axis might contribute to the amyloid deposition of AD. However, data about gut dysbiosis in human AD remains scarce in the literature, especially including the whole process of AD. In this prospective and cross-sectional study, we aimed at identifying differences in microbiome between patients with AD (Pre-onset stage amnestic mild cognitive impairment, aMCI; and AD) and the normal cognition healthy controls (HC). Additionally, the potential association between IM and clinical characteristics of AD was evaluated.METHODS:A total of 97 subjects (33 AD, 32 aMCI, and 32 HC) were recruited in the study. The composition of gut bacterial communities was determined by 16S ribosomal RNA Miseq sequencing. In addition, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict function shift of intestinal microbiota. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) or Clinical Dementia Rating (CDR) scores were used to evaluate the severity of cognitive impairment in patients.RESULTS:The fecal microbial diversity was decreased in AD patients compared with aMCI patients and HC. And the microbial composition was distinct among aMCI, AD and healthy control groups. Among bacterial taxa, the proportion of phylum Firmicutes was significantly reduced (P = 0.008), whereas Proteobacteria (P = 0.024) was highly enriched in the AD compared with HC. In addition, similar alterations were observed at the order, class and family levels of these two phyla. And Gammaproteobacteria, Enterobacteriales and Enterobacteriaceae showed a progressive enriched prevalence from HC to aMCI and AD patients. Further, a significant correlation was observed between the clinical severity scores of AD patients and the abundance of altered microbiomes. Moreover, the KEGG results showed the increased modules related to glycan biosynthesis and metabolism in AD and aMCI patients and decreased pathways related to immune system in AD patients. Importantly, the discriminating models based on predominant microbiota could effectively distinguish aMCI and AD from HC (AUC = 0.890, 0.940, respectively), and also AD from aMCI (AUC = 0.925). Notably, the models based on the abundance of family Enterobacteriaceae could distinguish AD from both aMCI (AUC = 0.688) and HC (AUC = 0.698).CONCLUSIONS:Distinct microbial communities, especially enriched Enterobacteriaceae, were associated with patients with AD when compared with predementia stage aMCI and healthy subjects. These novel findings will give new clues to understand the disease and provide new therapeutic target for intervention or a marker for this disease.

Comparative Epidemiological Investigation of Alzheimer’s Disease and Colorectal Cancer: the Possible Role of Gastrointestinal Conditions in the Pathogenesis of AD

Intestinal Microflora Changes in Patients with Mild Alzheimer's Disease in a Chinese Cohort.

Research Progress on the Correlation Between Chronic Constipation and the Gut Microbiota in the Elderly

[Association Between Lifestyle-Related Factors and Colorectal Adenoma].

Altered Microbiomes Distinguish Alzheimer's Disease from Amnestic Mild Cognitive Impairment and Health in a Chinese Cohort.

Prevalence of Constipation in Elderly and Its Association With Dementia and Mild Cognitive Impairment: A Cross-Sectional Study

The Association Between Constipation and Positron Emission Tomography and Blood-Based Biomarkers in Older Cognitively Unimpaired Adults with Higher Amyloid-β Burden

Gut Microbiota Mediates Neuroinflammation in Alzheimer’s Disease: Unraveling Key Factors and Mechanistic Insights

Epidemiology of chronic constipation:current status

The Complex Relationship Between Gut Microbiota and Alzheimer's Disease: A Systematic Review

Inhibition of colorectal cancer in Alzheimer's disease is mediated by gut microbiota via induction of inflammatory tolerance

Gut Microbiota: Implications in Alzheimer’s Disease

Gut microbiota and its metabolites: Bridge of dietary nutrients and Alzheimer’s disease

Microbiota Regulation in Constipation and Colorectal Cancer

A comparison of the composition and functions of the oral and gut microbiotas in Alzheimer's patients

Correlation between Alzheimer's Disease and Gastrointestinal Tract Disorders

Comprehensive 16S rRNA sequencing based microbiomes and 1H NMR based metabolomics reveal the relationships of aging and constipation

Association between the composite dietary antioxidant index and constipation: Evidence from NHANES 2005–2010

The association between constipation and the risk of colorectal cancer：a Meta-analysis

The Oral-Gut-Brain AXIS: the Influence of Microbes in Alzheimer's Disease.

Gut Microbiota And Alzheimer'S Disease: Pathophysiology And Therapeutic Perspectives